Following several years of planning, Baylor College of Medicine created a cancer center in 2002. C. Kent Osborne, M.D., was appointed director in 2004.
In 2006, Dan Duncan and his family made a $100 million transformative gift to support the College's vision and the center was named the Dan L Duncan Cancer Center. The following year the center achieved designation from the National Cancer Institute. Eight years later, the Duncan Cancer Center received Comprehensive status by the NCI for the breadth and depth of its research and commitment to serve all Houstonians, making the Dan L Duncan Comprehensive Cancer Center the newest of 47 Comprehensive Cancer Centers in the United States, and one of only three in Texas.
Since 2007, the Dan L Duncan Comprehensive Cancer Center has brought in $1.6 billion in funding in cancer research to Baylor College of Medicine.
Cancer center members have been at the forefront of many important discoveries driving improved patient outcomes.
The Duncan Cancer Center is a world leader in the genomics and proteomics of cancer and has pioneered the science that has led to hormonal and immunotherapeutic treatment of cancer. Researchers explore the relationship between the environment and biology that leads to cancer and identify new targets through this science to develop novel drugs and biomarkers.
The center has enrolled more than 5,400 patients to clinical trials since 2004. We are currently saving lives and improving care through innovational studies in CAR-T cell Immunotherapy, Precision Medicine and de-escalation of over-delivered treatment.
Through Baylor’s hospital partnerships, the Duncan Cancer Center is ranked No. 1 in the state of Texas for pediatric cancer at Texas Children’s Hospital and No. 2 in the state for adult cancer at Baylor St. Luke’s Medical Center by U.S. News and World Report.
We are proud to be a leader in community outreach, education and reducing health disparities in Texas.